International Journal of Cardiology
Volume 122, Issue 1 , Pages 52-55 , 31 October 2007

One year outcomes after glucose–insulin–potassium in ST elevation myocardial infarction. The Glucose–insulin–potassium study II

  • Saman Rasoul

      Affiliations

    • Department of Cardiology, Isala Klinieken, Zwolle, The Netherlands
    • ,
  • Jan Paul Ottervanger

      Affiliations

    • Department of Cardiology, Isala Klinieken, Zwolle, The Netherlands
    • Corresponding Author InformationCorresponding author. Isala Klinieken, Department of Cardiology, Groot Wezenland 20, 8011 JW Zwolle, The Netherlands. Tel.: +31 38 4242 198; fax: +31 38 4243 222.
    • ,
  • Jorik R. Timmer

      Affiliations

    • Department of Cardiology, Isala Klinieken, Zwolle, The Netherlands
    • ,
  • Tone Svilaas

      Affiliations

    • University Medical Center Groningen, University of Groningen, The Netherlands
    • ,
  • Jose P.S. Henriques

      Affiliations

    • Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Jan-Henk E. Dambrink

      Affiliations

    • Department of Cardiology, Isala Klinieken, Zwolle, The Netherlands
    • ,
  • Iwan C.C. van der Horst

      Affiliations

    • University Medical Center Groningen, University of Groningen, The Netherlands
    • ,
  • Felix Zijlstra

      Affiliations

    • University Medical Center Groningen, University of Groningen, The Netherlands

Received 10 August 2006 ,Accepted 2 November 2006.

References 

  1. Fath-Ordoubadi F, Beatt KJ. Glucose–insulin–potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152–1156
  2. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin–glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65
  3. Van der Horst IC, Zijlstra F, van't Hof AWJ, et al. Glucose–insulin–potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose–insulin–potassium study: a randomized trial. J Am Coll Cardiol. 2003;42:784–791
  4. Timmer JR, Svilaas T, Ottervanger JP, et al. Glucose–insulin–potassium infusion in patients with acute myocardial infarction without signs of heart failure: the glucose–insulin–potassium-study II. J Am Coll Cardiol. 2006;47:1730–1731[Letter]
  5. Mehta SR, Yusuf S, Diaz R, Zhu J, et al. CREATE-ECLA Trial Group Investigators. Effect of glucose–insulin–potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomised controlled trial. JAMA. 2005;293:437–446
  6. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650–661
  7. van der Horst IC, Timmer JR, Ottervanger JP, et al. GIPS Investigators. Glucose–insulin–potassium and reperfusion in acute myocardial infarction: rationale and design of the Glucose–Insulin–Potassium Study-2 (GIPS-2). Am Heart J. 2005;149:585–591
  8. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation. 1998;98:2227–2234
  9. Apstein CS, Opie LH. A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J. 2005;26:956–959
  10. Vanoverschelde JL, Janier MF, Bakke JE, Marshall DR, Bergmann SR. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Phys. 1994;267:H1785–H1794
  11. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26:1255–1261
  12. McGuire DK, Newby LK, Bhapkar MV, et al. Association of diabetes mellitus and glycaemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J. 2004;147:246–252
  13. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care. 1999;22:1827–1831
  14. Foo K, Cooper J, Deaner A, Knight C, et al. Single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart. 2003;89:512–516
  15. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48:298–304
  16. Apstein CS. Glucose–insulin–potassium infusion and mortality in the CREATE-ECLA trial. JAMA. 2005;293:2596–2597

☆ The GIPS-II study was made possible by a grant of the Netherlands Heart Foundation and from Guidant.

PII: S0167-5273(06)01445-8

doi: 10.1016/j.ijcard.2006.11.037

International Journal of Cardiology
Volume 122, Issue 1 , Pages 52-55 , 31 October 2007

Article Tools

* Image Usage & Resolution